Mitsubishi Tanabe Pharma Europe
GPTKB entity
Statements (46)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:Company
|
| gptkbp:collaboratesWith |
Research Institutions
Healthcare_Professionals |
| gptkbp:establishedIn |
2007
|
| gptkbp:focusesOn |
Research_and_Development
|
| gptkbp:hasPart |
Sales and Marketing Division
Clinical_Development_Division European_Headquarters |
| gptkbp:hasProductLine |
gptkb:Metformin
gptkb:Tobramycin gptkb:Acarbose gptkb:Saxagliptin gptkb:Sitagliptin gptkb:Linagliptin gptkb:Alogliptin gptkb:Radicava gptkb:Rosiglitazone gptkb:Semaglutide gptkb:Insulin_Glargine Dexamethasone Pioglitazone Lacosamide Mizoribine Canagliflozin Dapagliflozin Dulaglutide Empagliflozin Exenatide Liraglutide Miglitol Canagliflozin/Metformin Gliclazide Glimepiride Insulin Aspart Insulin Detemir Insulin Lispro Tirzepatide Vildagliptin |
| gptkbp:headquarteredIn |
gptkb:Amsterdam
|
| https://www.w3.org/2000/01/rdf-schema#label |
Mitsubishi Tanabe Pharma Europe
|
| gptkbp:offers |
Pharmaceutical_Products
|
| gptkbp:operatesIn |
Europe
|
| gptkbp:partOf |
gptkb:Mitsubishi_Tanabe_Pharma_Corporation
|
| gptkbp:specializesIn |
Immunology
Diabetes Neurology |